Blood monocyte phenotypes and soluble endotoxin receptor CD14 in systemic inflammatory diseases and patients with chronic renal failure.

AB. Antibiotic-associated pseudomembranous colitis due to should be used with caution in view of possible risk of toxin-producing clostridia. Where C. difficile infection persists despite conven-Walsh J. Clostridium difficile colitis associated with chronic renal tional treatment, there are limited data to identify the best treatment. Saccharomyces boulardii (yeast) is a difficile and the etiology of pseudomembranous colitis. Lancet therapy with no defined side-effects. The potential of 7. Wilcox MH. Clostridium difficile—setting the scene. J Antimicrob this therapy in this serious and sometimes life-threatening condition should be more widely publi-8. Brazier JS. The diagnosis of Clostridium difficile-associated disease. effectiveness with conventional therapies. Silva J. Clostridium difficile-associated diarrhoea and colitis. The lack of therapeutic effect of Acknowledgements. We thank Katie Fuller and other members of Saccharomyces boulardii in the prevention of antibiotic-related the infection control team, the nursing and medical staff on the diarrhoea in elderly patients. placebo-controlled trial of Saccharomyces boulardii in combina-DA. Under-described toxin in pseudomembranous colitis. Br tion with standard antibiotics for Clostridium difficile disease. membrane interactions which show chronic signs of